Business
Iambic Raises Over $100 Million in an Oversubscribed Round to Advance Its Portfolio of AI-Discovered Therapeutics and Leading Platform Technologies
SAN DIEGO, November 10, 2025--Iambic, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, today announced raising over $100 million in an oversubscribed financing round with balanced support from new and existing investors, including Abingworth, Alexandria Venture Investments, Alumni Ventures, ARK, Ascenta, Catalio, Everbright Biofund, Freeflow Ventures, Illumina Ventures, Mubadala, Pegasus Tech Ventures, Qatar I
About this update from Jazz Pharmaceuticals Plc
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2735,"height":751,"url":"https://media.zenfs.com/en/business-wire.com/8d09e7f181ad50e925f44829b850a811"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/7gLUSYeQQJUT7ZyyLAzZpQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI2NDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/8d09e7f181ad50e925f44829b850a811","width":960,"height":264},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/f_sf0GtD2EFWYjLUQEolRA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD02NjA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/8d09e7f181ad50e925f44829b850a811","width":1200,"height":330}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Support comes from new and existing investors, including life science, technology, growth, and sovereign wealth investors","length":121,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Financing closely follows announcements of Iambic’s clinical data for IAM1363 at the ESMO Congress and entry into a clinical collaboration with Jazz Pharmaceuticals","length":164,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":285,"olType":false},{"type":"text","content":"SAN DIEGO, November 10, 2025--(BUSINESS WIRE)--Iambic, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, today announced raising over $100 million in an oversubscribed financing round with balanced support from new and existing investors, including Abingworth, Alexandria Venture Investments, Alumni Ventures, ARK, Ascenta, Catalio, Everbright Biofund, Freeflow Ventures, Illumina Ventures, Mubadala, Pegasus Tech Ventures, Qatar Investment Authority, Regeneron Ventures, Sequoia, Tao Capital Partners, Terra Magnum Capital Partners, Wilson Sonsini Goodrich & Rosati, and others.","length":669,"tagName":"p"},{"type":"text","content":""We are thrilled to have the support of many outstanding and committed investors who are partnering with Iambic to advance our mission of creating technologies to bring better medicines to patients," said Tom Miller, PhD, Iambic Co-Founder and CEO. "We are proud of the scientific and business progress Iambic has made across its pipeline, partnerships, ...